NCT06265220 - AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 3, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions

Lupus Nephritis - WHO Class IIILupus Nephritis - WHO Class IVRefractory Systemic Lupus ErythematosusSLE

Interventions

DRUG

AB-101

NK Cell Therapy

DRUG

Cyclophosphamide

Lymphodepleting chemotherapy

DRUG

Fludarabine

Lymphodepleting chemotherapy

DRUG

Rituximab

Anti-CD20 antibody therapy

DRUG

Obinutuzumab

Anti-CD20 antibody therapy

Trial Locations (9)

28625

RECRUITING

Artiva Investigational Site Charlotte, Charlotte

33180

RECRUITING

Artiva Investigational Site Aventura, Aventura

33324

RECRUITING

Artiva Investigational Site Plantation, Plantation

35249

RECRUITING

Artiva Investigational Site Birmingham, Birmingham

52242

RECRUITING

Artiva Investigational Site Iowa, Iowa City

75150

RECRUITING

Artiva Investigational Site Mesquite, Mesquite

77382

RECRUITING

Artiva Investigational Site Woodlands, The Woodlands

85724

RECRUITING

Artiva Investigational Site Tucson, Tucson

92121

RECRUITING

Artiva Investigational Site San Diego, San Diego